Pulse Biosciences (NASDAQ:PLSE) Sees Large Volume Increase – Here’s What Happened

Pulse Biosciences, Inc (NASDAQ:PLSE) shares saw unusually-high trading volume on Thursday . 365,471 shares were traded during mid-day trading, an increase of 9% from the previous session’s volume of 334,136 shares.The stock last traded at $28.1040 and had previously closed at $28.11.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PLSE shares. Canaccord Genuity Group started coverage on shares of Pulse Biosciences in a report on Thursday, June 4th. They set a “buy” rating and a $32.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $30.67.

Pulse Biosciences Stock Performance

The company’s 50-day moving average is $25.10 and its 200-day moving average is $20.96. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -25.40 and a beta of 1.65.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.25 million. On average, analysts predict that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insider Buying and Selling

In related news, CEO Paul A. Laviolette acquired 15,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $19.69 per share, for a total transaction of $295,350.00. Following the transaction, the chief executive officer directly owned 15,000 shares of the company’s stock, valued at approximately $295,350. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Robert W. Duggan bought 660,233 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $19.69 per share, with a total value of $12,999,987.77. Following the transaction, the director owned 48,211,433 shares of the company’s stock, valued at $949,283,115.77. The trade was a 1.39% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 74.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PLSE. Bank of America Corp DE grew its position in shares of Pulse Biosciences by 8.2% during the 1st quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock worth $18,698,000 after buying an additional 65,884 shares during the period. Cetera Investment Advisers bought a new position in Pulse Biosciences in the first quarter valued at approximately $387,000. Tudor Investment Corp ET AL bought a new position in Pulse Biosciences in the fourth quarter valued at approximately $382,000. Inspire Investing LLC grew its holdings in Pulse Biosciences by 33.4% during the 4th quarter. Inspire Investing LLC now owns 34,192 shares of the company’s stock worth $469,000 after acquiring an additional 8,561 shares during the period. Finally, California State Teachers Retirement System grew its holdings in Pulse Biosciences by 23.2% during the 4th quarter. California State Teachers Retirement System now owns 21,165 shares of the company’s stock worth $291,000 after acquiring an additional 3,991 shares during the period. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.